Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2022-08-01 Director's Dealing
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-08-01 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-01 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-01 English
FORM S-8
Share Issue/Capital Change Classification · 95% confidence The document explicitly identifies itself as a "FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933" filed by Oramed Pharmaceuticals Inc. Form S-8 is used by companies to register securities offered under employee benefit plans, such as stock incentive plans. This filing type is not explicitly listed in the provided definitions (AGM-R, 10-K, AR, etc.). However, the purpose of an S-8 is to register shares for issuance, which falls under capital structure changes or financing activities related to employee compensation. Given the specific options, the closest fit that covers registration of securities for issuance, especially related to incentive plans, is 'Capital/Financing Update' (CAP), although it is primarily a registration statement. Since the options do not include 'S-8' or 'Registration Statement', and it deals with the issuance of stock under a plan, CAP is the most relevant category among the choices that deal with capital structure/financing, as opposed to being a report (10-K, IR) or a proxy/governance document. However, upon reviewing the definitions, none perfectly capture a Form S-8. Form S-8 is a specific SEC filing type. If we must choose from the list, and considering it registers shares for issuance under an incentive plan, it relates to capital structure. If it were a general announcement about the plan, it might fit elsewhere, but this is the actual registration document. Since it is a specific SEC filing that doesn't match the defined categories (like 10-K, DEF 14A, etc.), the fallback 'Regulatory Filings' (RNS) might be considered, but 'CAP' relates more directly to the substance (issuance of shares). Given the context of registering shares for an incentive plan, it is fundamentally a capital/financing action. I will classify it as CAP, acknowledging the imperfect fit, but it is more specific than the general RNS fallback.
2022-07-12 English
FORM S-8
Regulatory Filings Classification · 95% confidence The document is a filing from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange on 13/07/2022. The key content states: "Attached hereto is a report on *Form S-8*" followed by a filename. Form S-8 is a US SEC registration statement related to employee stock option plans. Since this document is an announcement *attaching* a specific regulatory form (Form S-8) rather than being the full content of a standard periodic report (like 10-K or IR), and it is a specific regulatory filing not covered by other codes (like DIV, DIRS, etc.), it best fits the general 'Regulatory Filings' category (RNS) or potentially a 'Report Publication Announcement' (RPA) because it announces the publication of another document. Given the explicit mention of attaching a specific SEC form (S-8), RNS is the most appropriate general regulatory fallback for non-standard, specific regulatory submissions that aren't the core reports listed.
2022-07-12 English
REGISTRATION STATEMENT
Regulatory Filings
2022-07-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.